28 January 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology. Read more…
Third cohort of cross-organizational, high-level mentorship program to commence in November 2025 Continued support from the Lundbeck Foundation and the Novo Nordisk Foundation WiLD celebrates its third anniversary with 250+ members in Denmark 28 October 2025, Denmark: Women in Life Science Denmark (WiLD) today announces that it is launching the third cohort of its successful […]
How can companies with promising science secure the capital they need to develop drugs What does pharma need to fill their pipelines as they look to negotiate looming patent cliffs London, UK, 7 October 2025: Optimum Strategic Communications (Optimum), the specialist life sciences communications consultancy, will be hosting its 17th Annual Healthcare Investor Conference on Thursday […]
DaltonTx, a UK-based technology company, today announces its exit from from stealth and the completion of a £4 million seed financing round to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D so breakthrough medicines reach patients faster. AI offers pharma a unique opportunity to discover medicines more effectively and […]
